Following the recent update on its obesity program, Pila Pharma is now opening a new front in its clinical development strategy. The company has initiated preparations for a clinical proof of concept study with its TRPV1-inhibitor, XEN-D0501, targeting the rare disease erythromelalgia. This move activates a well-established track in the company’s portfolio, aiming for a rapid and alternative path to market and revenue generation alongside the ongoing metabolic initiatives in obesity and diabetes.
Read the full article at biostock.se:
https://biostock.se/en/2026/02/pila-pharma-aktiverar-lukrativt-spar-inom-sarlakemedel/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se